Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure.
about
Role of endothelin in cardiovascular diseaseAmbrisentan, a non-peptide endothelin receptor antagonistEndothelin receptor antagonists and cerebral vasospasm: an update.Endothelin receptor antagonists and cardiovascular diseases of aging.Endothelin antagonists and heart failure.Endothelin-1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents.Endothelin receptor antagonists in cardiology clinical trials.Present and future pharmacotherapy for heart failure.Heart failure in 10 years time: focus on pharmacological treatment.Endothelin and endothelin receptor antagonists in heart failure.The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system.New therapies for the management of acute heart failure.Endothelin.Role of endothelins in congestive heart failure.Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic management.Drug therapy in chronic heart failure.Tezosentan in the treatment of acute heart failure.Combination pharmacologic therapies for heart failure: what next after angiotensin-converting enzyme inhibitors and beta-blockers?Ion channelopathy and hyperphosphorylation contributing to cardiac arrhythmias.The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?Future pharmacologic agents for treatment of heart failure in children.Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists?Endothelin-1, aging and hypertension.Left ventricular dysfunction with pulmonary hypertension: part 2: prognosis, noninvasive evaluation, treatment, and future research.The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies.Emerging therapies for heart failure: renal mechanisms and effects.Pulmonary vasodilation in acute and chronic heart failure: empiricism and evidence.Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening.Pathophysiology and potential treatments of pulmonary hypertension due to systolic left heart failure.Echocardiographic estimation of pulmonary capillary wedge pressure using the combination of diastolic annular and mitral inflow velocities.Emerging therapies for heart failure.Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy.Management of acute subdural hematoma in a patient with portopulmonary hypertension on prostanoid therapy.The role of endothelin converting enzyme inhibition during group B streptococcus-induced pulmonary hypertension in newborn piglets.Acute cardiopulmonary effects of a dual-endothelin receptor antagonist on oleic acid-induced pulmonary arterial hypertension in dogs.Cardiac effects of endothelin receptor antagonism in endotoxemic pigs.
P2860
Q28216230-120A91A4-B23A-4E95-A889-2A46274430F6Q28260732-52B510C7-E05F-4E1D-BFBA-490B03D5480AQ30310232-7689AD5F-17BC-43F3-B0AF-09EFFAD9ADD5Q34289891-C3C90040-62CD-4EBA-876C-C44EE01CFF49Q34492848-19EBFCF9-6A53-48FF-9546-476F20385146Q34496108-BF81F90F-5204-40D5-B269-60DF5B206A32Q34544685-48BCF442-F334-401D-BBEF-5D8CD70FF2A6Q34706912-96D49382-31FB-4B75-91B9-E777776DA44DQ34817094-53E105F9-9402-4D16-BA9B-F027D046D08BQ34943424-1D9529B4-DF08-4F8F-AC4D-A4A17B32F167Q35001002-BAD4432D-8DEB-4000-8481-61FA9F526762Q35105845-A40935D3-787C-4276-B43A-8225DFB8E5ABQ35120667-0F045DD1-3A87-4C42-A21D-8110DEAE884DQ35168419-DDC5EDD4-098C-4808-983A-641FE6B57014Q35200873-ADF90F2C-C92A-4D51-8544-DA3CEBF8157EQ35518236-CFBDE0E7-C61D-4359-951B-2EB72F208DB3Q35590982-8309A18C-4680-4A3D-A5A9-222902D26D57Q36203160-6478155E-C628-41A0-AC29-70B791B911FEQ36204496-34F6CB0E-12DA-4B82-9B03-0145EC69BF2FQ36510011-0108721A-5837-437B-9372-1B884728E546Q36577692-989D5295-BABC-4B8D-9338-B78E004E4A4CQ36674362-9F774204-1D83-4CE2-A8BC-4743763AC2A1Q36726832-E9D52770-FEDE-4A76-B9D8-2AD1A6233F6CQ36868978-63BCE0AF-136A-4701-833D-2DD86CE8E311Q37428038-5A1FE28D-AC27-46B0-8491-7925084CD41FQ37783956-2F6AA947-EF64-4E5E-BDD6-E4598E983731Q37873778-DFBC6F3D-A2C6-485B-BE92-E0A677A46B3AQ38191192-A198AB0E-FA07-474A-96BF-B8B94C7C0D79Q38202309-A88B20FD-BBC4-48D5-B269-DE3080BD5549Q39399607-736F9AC3-F6FF-4DBB-806F-36C490D20526Q40409363-F99A4E73-3CE0-44EF-996B-600E149BA233Q41054061-FEA4813D-4C3A-4236-96C6-134B5A5904D4Q41339390-FE83C06B-F1F6-47CC-A155-E448D0288501Q44467182-669B678A-227E-4CBA-A910-59FF8EBE2ACEQ44766880-82BFAE61-8B82-4915-AB4E-40D0B9A85A94Q54444024-3F0BA4C1-4CE8-4751-B2CF-1EF5004FD2F8
P2860
Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Hemodynamic effects of tezosen ...... o IV congestive heart failure.
@ast
Hemodynamic effects of tezosen ...... o IV congestive heart failure.
@en
type
label
Hemodynamic effects of tezosen ...... o IV congestive heart failure.
@ast
Hemodynamic effects of tezosen ...... o IV congestive heart failure.
@en
prefLabel
Hemodynamic effects of tezosen ...... o IV congestive heart failure.
@ast
Hemodynamic effects of tezosen ...... o IV congestive heart failure.
@en
P2093
P356
P1433
P1476
Hemodynamic effects of tezosen ...... o IV congestive heart failure.
@en
P2093
Torre-Amione G
P304
P356
10.1161/01.CIR.103.7.973
P407
P577
2001-02-01T00:00:00Z